Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217) is a long-acting glucagon-like peptide 1 (GLP-1) analogue, agonist of GLP-1 receptor. It has potential therapeutic efficacy for type 2 diabetes mellitus (T2DM).

Sommarutide is a peptide hormone that occurs naturally in the human body and has a variety of biological activities and medical applications. It mainly plays a role by regulating cell physiological processes such as cell proliferation, cell apoptosis, cell differentiation and cell migration.

The main uses of sommarutide are as follows:

1. Anti-cancer treatment: Sommarutide can be used as an anti-tumor drug to inhibit tumor progression by promoting tumor cell apoptosis and inhibiting tumor growth.

2. Breast cancer diagnosis: 1a-Domain, a derivative of sommarutide, is labeled and can selectively bind to breast cancer cells in vivo for early detection and diagnosis of breast cancer.

3. Tumor imaging: Somarlutide can be combined with radioisotopes or fluorescent dyes for molecular imaging of tumors and therapeutic navigation in imaging.

The synthesis method of sommarutide can be achieved by solid-phase synthesis or liquid-phase synthesis. In solid phase synthesis, protected amino acid synthesis units are used to gradually construct peptide chains on the solid phase. Then the target peptide is obtained by removing the amino acid protection group through the deprotection reaction. Liquid-phase synthesis usually involves linking the synthesized peptide chain to the carrier molecule and conducting a step-by-step ethyl ester or acylation reaction. There are some other synthesis methods, such as chemical liquid phase synthesis and chemical synthesis, can be selected according to the specific needs of the appropriate method.